辉瑞(PFE.US)旗下口服抗癌药Braftovi获FDA批准治疗结直肠癌

Core Viewpoint - The FDA has officially approved Braftovi, an oral cancer drug developed by Pfizer and Ono Pharmaceutical, for the treatment of colorectal cancer, based on Phase 3 BREAKWATER clinical trial data [1][2]. Group 1: FDA Approval and Clinical Data - Braftovi is approved as part of a combination therapy for previously untreated patients with metastatic colorectal cancer carrying the BRAF V600E mutation [1]. - The approval was granted through the accelerated approval pathway after achieving one of the dual primary endpoints related to overall response rate in the BREAKWATER study [1]. - The combination of Braftovi and the anti-cancer drug cetuximab resulted in a median progression-free survival of 12.8 months for newly diagnosed patients with BRAF V600E mutated metastatic colorectal cancer [1]. Group 2: Drug Composition and Patient Demographics - The active ingredient in Braftovi, encorafenib, is an oral small molecule BRAF inhibitor [2]. - BRAF mutations occur in up to 15% of metastatic colorectal cancer patients, who generally have a poor prognosis [2]. - Patients with BRAF V600E mutations have more than double the mortality rate compared to those with wild-type BRAF [2].